Trilostane For Cushing's Syndrome Treatment 13647-35-3

Payment Type: L/C,T/T,D/P,D/A
Min. Order: 1 Gram

Basic Info

Model No.: 13647-35-3

Additional Info

Productivity: Customized


Transportation: Ocean,Air

Place of Origin: CHINA

Supply Ability: COMMERCIAL

Product Description

Trilostane cas number 13647-35-3 is a new action mechanism of anti-estrogen new drugs, can reduce all endogenous steroids, including estrogen and androgen formation, since it was approved in the market,scholars have studied it for postmenopausal women late Breast cancer, and published a small report of the effective report. Then,after the expiration of the patent, BioEnvision company decided to further study trilostane. A series of clinical trials were conducted in postmenopausal women who were treated with tamoxifen has no response for progressive breast cancer women and registered in more than 780 patients in Europe, the United States and Australia. The results showed that trilostane has high activity on anticancer. Total effective rate was 42%, and the objective response rate to the hormone-sensitive subjects was as high as 55%, both of which were significantly better than the standard two-line drugs Enzyme inhibitors. In addition, older animals, especially older dogs, are susceptible to Cushing's syndrome, and trilostane cas 13647-35-3 can relieve symptoms of more than 90% of the dogs and improve their quality of life, so the drug is also approved in the UK.
Trilostane cas number 13647-35-3 itself has no hormonal activity, so its side effects are less, safety and tolerance are particularly good. Its safety is completely within the acceptable range, the main side effects are mild to moderate diarrhea and abdominal discomfort. However, trilostane can inhibit the production of adrenal hormones, so in the course of medication must be added corticosteroids, such as dexamethasone or hydrocortisone and so on.

Thera. Category: Anti-Cancer

Cas No.: 13647-35-3

Synonym: TRILOSTANE; androstane-2-carbonitrile,4,5-epoxy-17-hydroxy-3-oxo-,(2-alpha,4-alpha,5-al;modrenal


Molecular Formula: C20H27NO3

Molecular Weight: 329.43

Pharmacopeia: in house spe.

Specifications:Available on request

Packing:Export worthy packing

Material Safety Data Sheet:Available on request

Active Pharmaceutical Ingredients> Cas 90098-04-7,Rebamipide Named In Mucosta With GMP Standard
Active Pharmaceutical Ingredients> Functional Dyspepsia Treatment Acotiamide Hydrochloride Trihydrate CAS 773092-05-0
Active Pharmaceutical Ingredients> Acotiamide Hydrochloride For Gastric Motility Improvement CAS 185104-11-4
Contract Manufacturing> ASCORBYL GLUCOSIDE Used for Comesitc Additive CAS 129499-78-1
Pharmaceutical Intermediates> Anti-Ulcerative> 2-Aminothiazole-4-ethylformate For Making Acotiamide Cas 5398-36-7
Pharmaceutical Intermediates> Anti-Ulcerative> Acotiamide INT CAS NUMBER 185105-98-0
Pharmaceutical Intermediates> Anti-Cardiovascular> Azilsartan Used for Hypertension Treatment CAS 147403-03-0
Pharmaceutical Intermediates> Anti-Diabetes> Sitagliptin Phosphate Monohydrate Treated for Type 2 diabetes CAS Number 654671-77-9
Pharmaceutical Intermediates> Anti-Ulcerative> Cas 132210-24-3, 2-Amino-3-(1,2-dihydro-2-oxo-quinoline-4-yl)Propanoic acid Hydrochloride For Rebamipide
Pharmaceutical Intermediates> Anti-Ulcerative> Cas 1068-90-2 White Crystalline Powder Diethyl Acetamidomalonate For Rebamipide(DAAM)
Active Pharmaceutical Ingredients> 6027-23-2, Hordenine HCL Powder
Pharmaceutical Intermediates> Anti-Ulcerative> Cas 4876-10-2,4-Bromomethyl-2(1H)-quinolinone (BMQ) For Rebamipide/ Mucosta
Pharmaceutical Intermediates> Anti-Respiratory> CAS 2338-18-3, 2-Aminoindan hydrochloride For Making Indacaterol
Pharmaceutical Intermediates> Anti-Respiratory> CAS 312753-53-0/ 5,6-Diethyl-2,3-dihydro-1H-inden-2-amine hydrochloride Used for Indacaterol
Pharmaceutical Intermediates> Anti-Respiratory> 312753-53-0, Indacaterol Intermediate
Pharmaceutical Intermediates> Anti-Respiratory> 100331-89-3, Indacaterol Intermediate

© 2019 CHINA WAY. All Rights Reserved.  Taizhou Volsen Chemical Co., Ltd.,  Inc.   All rights reserved. site map.  sitemap.html